SHUKLA SANJAY (President and CEO) purchased 19.7% of their position (15K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $16.7K — a significant purchase. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 11/13/2023ACC: 0001209191-23-054976
Officer· President and CEO
Since Feb 2019
+15K
Net shares
Net buyer
$16.7K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
15K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+1.42K
Price / share
$1.14
Trade value
$1.62K
% of position
1.9%
11/10/2023
76.17K→77.59K
Common Stock
Direct
Shares
+13.58K
Price / share
$1.11
Trade value
$15.09K
% of position
17.5%
11/13/2023
77.59K→91.17K
Total
Net shares
+15K
Net value
$16.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/10/2023 | P · Purchase | +1.42K | $1.14 | $1.62K | 1.9% | 76.17K | 77.59K |
| Common Stock Direct | 11/13/2023 | P · Purchase | +13.58K | $1.11 | $15.09K | 17.5% | 77.59K | 91.17K |
| Total | +15K | $16.70K | ||||||
Derivative Transactions0
No derivative transactions reported